Week 2 Flashcards
Characterized by infection of the tracheobronchial tree that results in hyperemic and edematous mucous membranes, yielding an increase in bronchial secretions .
Acute bronchitis
Most common virus causing acute bronchitis:
Rhinovirus
Hallmark of acute bronchitis:
Dry/nonproductive cough
General treatment for acute bronchitis:
Symptomatic and supportive care, antitussives, bronchodilators
Productive cough and sputum production for 3 months per year for at least 2 consecutive years
Chronic bronchitis
3 cardinal symptoms of COPD exacerbations:
- Increase in dyspnea
- Increase in sputum production
- Increase or presence of sputum purulence
An infection in the lungs that leads to consolidation of the usually air-filled alveoli.
CAP
Most common pathogen of CAP:
S. Pneumoniae
Diagnostic criteria for CAP:
Patients present with cough, fever, dyspnea, malaise, pleuritic chest pain, CXR
Antibiotic treatment for patients with CAP without recent antibiotic use or existing Comorbidity:
Macrolides- azithromycin or clarithro
Or doxy
Antibiotics in treatment of CAP in patients of comorbidity:
High-dose amoxicillin, augmentin, or 2nd/3rd generation cephalosporin plus a macrolide, or a fluoroquinolone alone.
With CAP what antibiotic can be used in patients allergic to azithromycin?
Doxycycline
What antibiotic should not be used in CAP treatment:
Cipro
In children, antibiotics are typically not required; however, if needed what do you use?
Amoxicillin
Characterized by airway narrowing and Airway hyper-responsiveness.
Asthma
Airflow obstruction is present when the FEV1/FVC ratio is less than:
0.70
All patients with asthma, regardless of severity, require:
Short-acting beta2-adrenergic agonist (SABA) bronchodilator for quick relief of acute symptoms
When can treatment be stepped down with asthma?
When symptoms have been well controlled for 3 months
How to step down asthma treatment:
- Oral corticosteroids are reduced and d/c’d first
- Dose of inhaled corticosteroids May then be reduced by 50%
- Long-term control regimen may be stopped if the person with asthma has been free of symptoms for 6-12 months and has no risk of exacerbations
MOA of beta2-adrenergic agonist:
Stimulate the beta2-adrenergic receptors, increasing production of the cAMP. Increased cAMP relaxes the airway smooth muscle and increases bronchial ciliary activity.
All beta2-adrenergic agonists have:
Slight CV stimulatory effects including increased HR, cardiac contractility, and increased cardiac conductivity
Examples of SABAS:
Albuterol and levalbuterol
Example of long-term beta2-adrenergic agonist:
Salmeterol- used in chronic maintenance
Formoterol- quicker onset of action
Both have duration of action of 12 hours.
Both are beta2 selective.
Contraindications with beta2-adrenergic agonist:
Use in caution in patients with CV disease, arrhythmia, DM, glaucoma, hyperthyroidism, or seizure disorder
Adverse events with both SABAS and LABAs:
Tachycardia, skeletal muscle tremor, nervousness, dizziness, hypokalemia, and hyperglycemia.
What antibiotic given for H. Flu bronchitis?
Amoxicillin
What antibiotic given for m. Catarrhalis bronchitis?
Augmentin
What antibiotic given for m. Pneumoniae bronchitis?
Macrolides or doxy
How long to treat with antibiotics for CAP?
At least 5 days and must be afebrile 48-72 hours prior to stopping.
When to order an CXR?
Any pt with at least one of the following: 1. Temp greater than 100 2. Heart rate over 100 3. RR over 20 Any patient with at least 2 of the following: 1. Decreased BS 2. Crackles 3. Absence of asthma
Hospital admission criteria: CURB-65
C: confusion- perform mini mental U: uremia- BUN greater than 20 R: RR greater than 30 B: low BP- systolic less than 90; diastolic less than 60 65: 65 years of age and older
Typically need 2 of these for admission
Asthma classification with exacerbations 2 times a week or less:
Intermittent
Asthma classification with more than 2 exacerbations a week but not daily:
Mild persistent
Asthma classification with daily symptoms and daily use of SABA:
Moderate persistent
Asthma classification with symptoms throughout the day and use of SABA several times daily:
Severe persistent
Bronchodilators in asthma are:
Relievers
Anti-inflammatory agents in asthma are:
Controllers
Drug/drug interactions with beta2-adrenergic agonist:
MAOIs or tricyclic antidepressants increase BP and risk of stroke. Must be discontinued at least 14 days prior to initiating a beta2-adrenergic agonist.
The most potent airway smooth muscle relaxant that is not beta2 selective:
Epinephrine
LABAs in asthma must always be used with:
ICS
What is safest SABA in kids under 4 and infants?
Albuterol
Most potent ICS:
Flovent
ICS with beta2-agonist have what type of effect:
Synergistic
ICS are indicated for all persons with persistent asthma t/f?
True
Low dose- mild persistent
Med dose- moderate persistent
High dose- severe persistent
Timing of inhalers:
Administer beta agonist first: opens the airway
MOA of inhaled steroids in asthma:
Anti-inflammatory action- binds to glucocorticoid receptors in the airway
Also inhibits mucus secretions in airways
A chemical mediator that can cause inflammatory changes in the lungs.
Leukotriene
MOA of leukotriene receptor antagonists:
Reduce inflammatory symptoms of asthma triggered by allergic and environmental stimuli.
Are leukotriene modifiers used for acute attacks?
No
Examples of leukotriene modifiers:
Singulair (montelukast)
Accolate (zafirlukast)
Zileuton (zyflo)
Adverse events of leukotriene modifiers:
HA*, churg-Strauss syndrome, systemic vasculitis, and behavioral changes
Montelukast is approved for ages:
Zafirlukast is approved for ages:
Zileuton is approved for ages:
Greater than 1 year of age
Greater than 5
Greater than 12
MOA of mast cell stabilizers:
Prevent release of inflammatory and bronchoconstricting substances from mast cells.
Examples of a mast cell stabilizer:
Cromolyn (intal) inhalation, prophylactic, take daily, good for kids
Methylxanthines MOA:
Relax smooth bronchial muscle, enhance diaphragmatic contractility, and have alight anti-inflammatory effect.
Examples of methylxanthines:
Theophylline and aminophylline
Methylxanthines are contraindicated in:
Use in caution In patients with Tachyarrhythmias, PUD, seizure disorders, and hyperthyroidism.
Adverse events of methylxanthines:
Tachyarrhythmias, HA, restlessness, insomnia, tremor, N/V*, gastroesophageal reflux, and peptic ulcer aggravation.
Monitor serum levels in methylxanthines due to:
Narrow therapeutic window
Immunomodulators:
Omalizumab (Xolair)
Xolair MOA:
Decreases binding of IgE on surface of the mast cells which decreases allergic response
Xolair indications:
Patients with severe allergies and severe persistent asthma
Xolair is given:
SubQ every 2-4 weeks
Adverse events of Xolair?
High risk of anaphylaxis
What to do for exercise induced bronchospasm?
SABA 15 minutes prior to exercise
A mast cell stabilizer of short acting anticholinergic can be given when SABA is ineffective
Mild-intermittent asthma managed with:
SABA
Mild persistent asthma (step 2) managed with:
Low dose ICS
Alternative: cromolyn, montelukast
Moderate persistent (step 3-4) asthma managed with
Low to medium dose ICS plus LABA or medium dose ICS
Severe persistent (5-6) asthma managed with:
High dose ICS plus LABA
Xolair May be added for what type of asthma?
Confirmed allergic asthma
Systemic corticosteroids are used In asthma for:
Treatment of acute asthma exacerbation
Systemic corticosteroids used in exacerbation administration info:
40-60 mg daily x 5 days
Administer at 3 pm
Can cause insomnia
SABA can be given how frequently during an exacerbation:
2-6 puffs every 20 minutes
Diagnostic criteria for COPD:
A post-bronchodilator FEV1/FVC less than 70% signifies a fixed airway obstruction
A post-bronchodilator FEV1/FVC with asthma will:
Increase by greater than 12% or 200 ml
Group A treatment in COPD:
Bronchodilators
Group B treatment in COPD:
Initial- LAMA or LABA
If continued breathlessness- 2 bronchodilators (LABA and LAMA)
Group C therapy in COPD:
Initial- LAMA
Persistent exacerbations- add LABA or LABA and ICS
Group D treatment in COPD:
Initial- LABA/LAMA combo or LAMA and LABA/ICS
Phosphodiesterase 4 inhibitors MOA:
inhibits phosphodiesterase 4, this inhibition increases cellular cAMP, modifying the inflammatory response.
Causes bronchodilation with anti-inflammatory effects
Phosphodiesterase 4 inhibitors include:
Daxas (dalisrep)
Adverse events with phosphodiesterase 4 inhibitors:
Increase risk of suicide and weight loss
COPD exacerbation cardinal signs:
Increase in dyspnea
Increase in sputum volume
Increase in sputum purulence**
Treatment if COPD exacerbation:
Increasing dose/frequency of SABA or SAMA
5 day course of oral steroids: 40mg
Antibiotics 5-10 days
Antibiotics for COPD exacerbation:
1st line- macrolides
Augmentin
Doxycycline
Do not take oral steroids with:
Antacids due to decreases absorption
What beta2 agonist is ok in pregnancy?
Terbutaline
Salmeterol should never:
Be used in children under 4 or as monotherapy
Beta agonists can increase the QT prolongation when given with what drugs?
Loop/thiazide diuretics, other sympathomimetics